1
|
Terzani F, Belhattab S, Le Guern A, Guitot K, Monasson O, Zanato C, Chelain E, Leroy-Dudal J, Pytkowicz J. Synthesis and biological evaluation of selective Pepstatin based trifluoromethylated inhibitors of Cathepsin D. Eur J Med Chem 2024; 267:116178. [PMID: 38295686 DOI: 10.1016/j.ejmech.2024.116178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 01/22/2024] [Accepted: 01/23/2024] [Indexed: 02/25/2024]
Abstract
Cathepsin D (CD) is overexpressed in several types of cancer and constitutes an important biological target. Pepstatin A, a pentapeptide incorporating two non-proteinogenic statin residues, is among the most potent inhibitor of CD but lacks selectivity and suffers from poor bioavailability. Eight analogues of Pepstatin A, were synthesized, replacing residues in P3 or P1 position by non-canonical (S)- and (R)-α-Trifluoromethyl Alanine (TfmAla), (S)- and (R)-Trifluoromethionine (TFM) or non-natural d-Valine. The biological activities of those analogues were quantified on isolated CD and Pepsin by fluorescence-based assay (FRET) and cytotoxicity of the best fluorinated inhibitors was evaluated on SKOV3 ovarian cancer cell line. (R)-TFM based analog of Pepstatin A (compound 6) returned a sub-nanomolar IC50 against CD and an increased selectivity. Molecular Docking experiments could partially rationalize these results. Stabilized inhibitor 6 in the catalytic pocket of CD showed strong hydrophobic interactions of the long and flexible TFM side chain with lipophilic residues of S1 and S3 sub-pockets of the catalytic pocket. The newly synthesized inhibitors returned no cytotoxicity at IC50 concentrations on SKOV3 cancer cells, however the compounds derived from (S)-TfmAla and (R)-TFM led to modifications of cells morphologies, associated with altered organization of F-actin and extracellular Fibronectin.
Collapse
Affiliation(s)
- Francesco Terzani
- CY Cergy Paris Université, CNRS, BIOCIS UMR 8076, 95000, Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS UMR 8076, 91400, Orsay, France.
| | - Sherazade Belhattab
- CY Cergy Paris Université, CNRS, BIOCIS UMR 8076, 95000, Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS UMR 8076, 91400, Orsay, France.
| | - Aurore Le Guern
- CY Cergy Paris Université, CNRS, BIOCIS UMR 8076, 95000, Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS UMR 8076, 91400, Orsay, France.
| | - Karine Guitot
- CY Cergy Paris Université, CNRS, BIOCIS UMR 8076, 95000, Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS UMR 8076, 91400, Orsay, France.
| | - Olivier Monasson
- CY Cergy Paris Université, CNRS, BIOCIS UMR 8076, 95000, Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS UMR 8076, 91400, Orsay, France.
| | - Chiara Zanato
- CY Cergy Paris Université, CNRS, BIOCIS UMR 8076, 95000, Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS UMR 8076, 91400, Orsay, France.
| | - Evelyne Chelain
- CY Cergy Paris Université, CNRS, BIOCIS UMR 8076, 95000, Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS UMR 8076, 91400, Orsay, France.
| | - Johanne Leroy-Dudal
- Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe, (EA1391), Groupe Matrice Extracellulaire et Physiopathologie (MECuP), CY Cergy Paris Université, Neuville sur Oise, France.
| | - Julien Pytkowicz
- CY Cergy Paris Université, CNRS, BIOCIS UMR 8076, 95000, Cergy Pontoise, France; Université Paris-Saclay, CNRS, BioCIS UMR 8076, 91400, Orsay, France.
| |
Collapse
|
2
|
Ben Haj Salah K, Terzani F, Pietri M, Zanato C, Chelain E, Pytkowicz J. Highly Stereoselective Multigram Scale Synthesis of (3S,4S)-Statine and (3S,4S)-N-Benzylstatine. Results in Chemistry 2022. [DOI: 10.1016/j.rechem.2022.100333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
3
|
Rusche H, Marrani E, Real-Fernandez F, Ponti R, Terzani F, Maccora I, Monasson O, Mastrolia MV, Peroni E, Pagnini I, Cimaz R, Papini AM, Simonini G, Rovero P. A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis. Sci Rep 2021; 11:16393. [PMID: 34385564 PMCID: PMC8360964 DOI: 10.1038/s41598-021-95920-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Accepted: 07/26/2021] [Indexed: 11/30/2022] Open
Abstract
Immune response to biologics treatment, while widely reported, yet fails to correlate with clinical outcomes and assay to assay comparison is often not possible. Hence, we developed a new peptide based-detection assay to stratify pediatric patients with juvenile idiopathic arthritis (JIA) or chronic non-infectious uveitis (CNU) and monitor anti-drug antibodies (ADAbs) formed as part of an immune response to treatment with the fully human monoclonal therapeutic antibody Adalimumab. Adalimumab derived synthetic peptides were optimized for maximum immunogenicity and were tested by SP-ELISA on a development cohort of 18 JIA and CNU treated patients. The two best performing peptides able to differentiate patient groups were selected for evaluation with a larger scale ELISA testing on a total of 29 sera from pediatric patients with JIA or CNU. The results of this peptide-based assay were compared to an in-house developed SPR biosensor ADAbs assay and a commercially available bridging ELISA. The first peptide, termed HC3, was able to positively detect ADAbs in 7 out of the 29 sera, while the second peptide, called LC3, was able to detect ADAbs in 11 out of 29 sera in the evaluation group. Following statistical data evaluation, it has been found that the detection of ADAbs using the peptide-based ELISA assay positively correlates with disease progression and remission. Two synthetic peptides derived from Adalimumab may provide a beneficial tool to clinicians for monitoring patient response to such treatment and taking informed decisions for treatment alternatives.
Collapse
Affiliation(s)
- Hendrik Rusche
- Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, CY Cergy Paris Université, Neuville sur Oise, France.,Fischer analytics GmbH, Weiler, Germany
| | | | - Feliciana Real-Fernandez
- Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy
| | - Roberta Ponti
- Department of Medicine, University Hospital of Udine, Udine, Italy
| | - Francesco Terzani
- Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, CY Cergy Paris Université, Neuville sur Oise, France.,Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy
| | | | - Olivier Monasson
- Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, CY Cergy Paris Université, Neuville sur Oise, France
| | | | - Elisa Peroni
- Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, CY Cergy Paris Université, Neuville sur Oise, France
| | | | - Rolando Cimaz
- Department of Clinical Sciences and Community Health, University of Milano, Milan, Italy
| | - Anna Maria Papini
- Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, CY Cergy Paris Université, Neuville sur Oise, France.,Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy
| | - Gabriele Simonini
- Pediatric Rheumatology Unit, AOU Meyer, Florence, Italy. .,Department of NeuroFarBa, University of Florence, Florence, Italy.
| | - Paolo Rovero
- Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy.
| |
Collapse
|